Memorial Sloan Kettering Cancer Center

City University of New York

Brian Zeglis

Jason S Lewis

Thomas Reiner

Christian Brand

Jacob Lee Houghton

Pierre Adumeau

Jan-Philip Meyer

Maria Davydova

Described herein are Tz/TCO-based pretargeting strategies using an Al[F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-basedF imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life,F is more readily available to produce and therefore integrated into hospital workflows.

Radioligands for pretargeted pet imaging and methods of their therapeutic use

A label for an antibody or protein is described that is both site-selective and unusually stable in vivo. The label has a general formula given by Formula (I) wherein Ris a metal chelator, a fluorophore or a click-chemistry synthon. 

Reagent for site-selective bioconjugation of proteins or antibodies

Growing community of inventors

New York, NY, United States of America

Brian Zeglis